BCM
CTNM

Bridgeway Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Bridgeway Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644K Hold
49,280
– – 0.01% 781
2025
Q4 		$563K Buy
49,280
+7,700
+19% +$87.9K 0.01% 796
2025
Q3 		$489K Buy
41,580
+22,380
+117% +$180K 0.01% 810
2025
Q2 		$76.2K Buy
+19,200
New +$83.4K ﹤0.01% 1102

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bridgeway Capital Management's CTNM Position: Q1 2026 in Review

Bridgeway Capital Management held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 49,280 shares worth $644K. The position accounts for 0.01% of the portfolio, ranked #781.

Bridgeway Capital Management first reported a position in CTNM in Q2 2025 and has held it in 4 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Bridgeway Capital Management held 49,280 shares of Contineum Therapeutics worth $644K as of Q1 2026.
  • Bridgeway Capital Management left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #781 holding.
  • Bridgeway Capital Management first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.